Treatment of Rivaroxaban Versus Aspirin for Non-disabling Cerebrovascular Events
Status:
Unknown status
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
Transient ischemic attack (TIA) or minor ischemic stroke has a high risk of early recurrent
stroke. As the golden standard, aspirin effect modestly on acute ischemic stroke, and
slightly increase the risk of intracerebral hemorrhage. Recently, rivaroxaban, a new oral
anticoagulant, is proved to be as effective as traditional anticoagulants, while carrying
significantly less risk of intracranial hemorrhage.
The TRACE trial is a randomized, double-blind, multicenter, controlled clinical trial in
China. The investigators will assess the hypothesis that a 30-days rivaroxaban regimen is
superior to aspirin alone for the treatment of high-risk patients with acute nondisabling
cerebrovascular event.